Patent US4929602A successfully refreshed from Google Patents.
US4929602A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of inhibiting platelet dependent arterial thrombosis
Assignee: Scripps Research Institute
•
Filing: 1988-11-22
•
Granted: 1990-05-29
•
Expires: 2008-11-22
Abstract
Abstract The present invention contemplates a method of preventing platelet dependent arterial thrombosis using a halogen-methyl ketone-containing peptide represented by Formula (1) as shown in FIG. 1, or a hydrohalic addition product thereof. More particularly, the present invention provides improved methods for inhibiting arterial restenosis, hemodialysis and the like.
Inventors
- 👤 Laurence A. Harker
- 👤 Stephen R. Hanson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 17:15
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/04; A61K38/06; A61P; A61P7/00; A61P7/02; A61P9/00; A61P9/10
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
52 words
A method of inhibiting platelet dependent arterial thrombosis in a patient which method comprises administering to said patient a therapeutically effective amount of peptide represented by Formula 1 ##STR1## wherein Z is hydrogen or a C 1 -C 6 acyl; X is a halogen atom; and the hydrohalic acid addition products thereof.
Claim 2
Independent Claim
52 words
A method of inhibiting platelet dependent arterial thrombosis in a patient which method comprises administering to said patient a therapeutically effective amount of peptide represented by Formula 1 ##STR1## wherein Z is hydrogen or a C 1 -C 6 acyl; X is a halogen atom; and the hydrohalic acid addition products thereof.
Claim 3
Dependent Claim
13 words
The method of claim 1 wherein X is chlorine and Z is hydrogen.
Claim 4
Independent Claim
99 words
A method of inhibiting arterial restenosis in a patient, which method comprises: (a) administering to said patient a therapeutically effective amount of a peptide represented by Formula 1 ##STR2## wherein Z is hydorgen or a C 1 -C 6 acyl group; X is a halogen atom; and the hydrohalic acid addition products thereof, (b) subjecting said patient to endarterectomy, angioplasty or treatment with a therapeutically effective amount of a thrombolytic agent to increase the blood flow channel diameter in a stenosed artery to produce a treated artery, and (c) circulating arterial blood of said patient through said treated artery.
Claim 5
Independent Claim
99 words
A method of inhibiting arterial restenosis in a patient, which method comprises: (a) administering to said patient a therapeutically effective amount of a peptide represented by Formula 1 ##STR2## wherein Z is hydorgen or a C 1 -C 6 acyl group; X is a halogen atom; and the hydrohalic acid addition products thereof, (b) subjecting said patient to endarterectomy, angioplasty or treatment with a therapeutically effective amount of a thrombolytic agent to increase the blood flow channel diameter in a stenosed artery to produce a treated artery, and (c) circulating arterial blood of said patient through said treated artery.
Claim 6
Dependent Claim
26 words
The method of claim 3 wherein the amount of said peptide is sufficient to achieve a peptide concentration in the blood of at least 0.2 ug/ml.
Claim 7
Dependent Claim
26 words
The method of claim 3 wherein the amount of said peptide is sufficient to achieve a peptide concentration in the blood of at least 1 ug/ml.
Claim 8
Dependent Claim
27 words
The method of claim 5 wherein the amount of said peptide is sufficient to maintain said peptide concentration for a time period of at least 5 minutes.
Claim 9
Dependent Claim
35 words
The method of claim 5 wherein the amount of said peptide is sufficient to maintain said concentration of the blood for a time period of at least 5 minutes but no more than 90 minutes.
Claim 10
Dependent Claim
13 words
The method of claim 3 wherein X is chlorine and Z is hydrogen.
Claim 11
Dependent Claim
16 words
The method of claim 3 wherein said thrombolytic agent is streptokinase, urokinase or tissue plasminogen activator.
Claim 12
Dependent Claim
12 words
The method of claim 3 wherein (a) is performed prior to (c).
Claim 13
Dependent Claim
21 words
The method of claim 10 wherein (c) is performed while said peptide concentration in the blood is at least 1 ug/ml.
Claim 14
Dependent Claim
15 words
The method of claim 10 wherein (c) is performed within 5 minutes of performing (a).
Claim 15
Independent Claim
69 words
A method of inhibiting platelet deposition on an arterial prosthetic surface in a patient, which method comprises: (a) administering to said patient a therapeutically effective amount of a peptide represented by Formula 1 ##STR3## wherein Z is hydrogen or C 1 -C 6 acyl group; X is a halogen atom; and the hydrohalic acid addition products thereof, (b) contacting circulating arterial blood of said patient with a prosthetic surface.
Claim 16
Independent Claim
69 words
A method of inhibiting platelet deposition on an arterial prosthetic surface in a patient, which method comprises: (a) administering to said patient a therapeutically effective amount of a peptide represented by Formula 1 ##STR3## wherein Z is hydrogen or C 1 -C 6 acyl group; X is a halogen atom; and the hydrohalic acid addition products thereof, (b) contacting circulating arterial blood of said patient with a prosthetic surface.
Claim 17
Dependent Claim
26 words
The method of claim 13 wherein the amount of said peptide is sufficient to achieve a peptide concentration in the blood of at least 0.2 ug/ml.
Claim 18
Dependent Claim
26 words
The method of claim 13 wherein the amount of said peptide is sufficient to achieve a peptide concentration in the blood of at least 1 ug/ml.
Claim 19
Dependent Claim
27 words
The method of claim 15 wherein the amount of said peptide is sufficient to maintain said peptide concentration for a time period of at least 5 minutes.
Claim 20
Dependent Claim
35 words
The method of claim 15 wherein the amount of said peptide is sufficient to maintain said concentration in the blood for a time period of at least 5 minutes but no more than 90 minutes.
Claim 21
Dependent Claim
13 words
The method of claim 16 wherein X is chlorine and Z is hydrogen.
Claim 22
Dependent Claim
17 words
The method of claim 13 wherein said thrombogenic surface is an arterial prosthesis or an arteriovenous shunt.
Claim 23
Dependent Claim
12 words
The method of claim 13 wherein (a) is performed prior to (b).
Claim 24
Dependent Claim
21 words
The method of claim 20 wherein (b) is performed while said peptide concentration in the blood is at least 0.2 ug/ml.
References Cited (Backward Citations)
US4318904A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-05-28 | 1993-11-27 | 1994-05-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-05-28 | 1997-11-27 | 1998-05-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-05-28 | 2001-11-27 | 2002-05-29 | $7700.00 | Window Closed / Lapsed |